Industry Focus

Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.

Direct download: 20171213_IF_Healthcare.mp3
Category:Podcast -- posted at: 4:24pm EST

1